RxDoctor Payments Data

Albert Marcano

Primary Care · Jackson Heights, NYNPI 1861572562

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 462 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,333in general payments, 2019–2025

Across 462 payments — averaging $33.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Bayer$1K
  • Novo Nordisk$1K
  • Amgen$1K
  • Esperion Therapeutics, Inc.$633
  • plus $5K from 31 others

What the payments were for

  • Food & beverage$15,320100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,333 in reported general payments places this provider in the 95th percentile of 239 primary care providers in New York.

See all primary care providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$81,151
Diclofenac Potassium29$68,437
TrulicityDulaglutide44$62,695
OzempicSemaglutide43$50,441
KerendiaFinerenone41$46,992
FarxigaDapagliflozin Propanediol34$40,406
XareltoRivaroxaban35$31,498
JanumetSitagliptin Phos/Metformin Hcl28$30,436
JanuviaSitagliptin Phosphate29$26,893
ProliaDenosumab15$24,334
EliquisApixaban25$24,132
Diclofenac Sodium194$23,405
VascepaIcosapent Ethyl40$16,435
TradjentaLinagliptin14$16,211
LinzessLinaclotide20$14,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$508$97,36190 claims
Lilly USA, LLCTrulicity$454$62,69544 claims
MerckJanumet, Januvia$563$57,32957 claims
Novo NordiskOzempic$1,284$50,44143 claims
BayerKerendia$1,424$46,99241 claims
AstraZenecaFarxiga$2,069$40,40634 claims
Johnson & JohnsonXarelto$167$31,49835 claims
AbbVieLinzess, Qulipta$3,283$27,78733 claims
AmgenProlia$1,170$24,33415 claims
PfizerEliquis$545$24,13225 claims
GSKShingrix$34$10,63856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 primary care providers in New York.

Other primary care in Jackson Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →